| 摘要 |
An arylpiperazine derivative or a pharmaceutically acceptable salt or ester has the formula (I) wherein: Ring A is a optionally substituted 5-7 membered aliphatic ring; Ring B is a monocyclic or bicyclic alkyl, aryl, aralkyl, heteroaryl or heteroalkyl containing one or more heteroatoms of N, S or O or is biphenyl or ring B can be linked to ring A with alkyl or alkoxy chain linking the 2-position of ring B with the carbon atom a to X2; each R3 is H, halogen, NO2, COOR, CN, CF3, alkyl, S-alkyl, SO-alkyl, SO2-alkyl, alkoxy, aryloxy; n1 is 1 to 3; R is H or alkyl; P is -(CH2)n2-, alkene or alkyne chain or when X2 is carbon P may be Het, -(CH[R6])n3-Het, Het-(CH[R6])n3- or Het-(CH[R6])n3-Het; or P is -CON(R6)-, -N(R6)-CO-, -SO2-N(R6)- or -N(R6)-SO2; Het is CO, S, SO, SO2, NR6 or O; n3 is 1 or 2; X1 and X2 are independently nitrogen or carbon; Y is ûSO2- or ûCO-; Z is -CONHOH, Y is CO and Q is -C(R6)(R7)-, -C(R6)(R7)-CH2, N(R6)- or -N(R6)-CH2- or Z is -CONHOH, Y is SO2 and Q is -C(R6)(R7)- or -C(R6)(R7)-CH2 or Z is -N(OH)-CHO and Q is -C(R6)(R7)-, -C(R6)(R7)-CH2 or -N(R6)-CH2-; R1 is H or optionally substituted alkyl, cycloalkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl or is 2,3,4,5,6-pentafluorophenyl provided that where R1 is substituted by OH, OR4 or -N-Y-R4 Z is not -N(OH)-CHO; R2 is H, alkyl or together with R1 can form a carbocyclic or heterocyclic spiro 5 to 7 membered ring with the heterocyclic ring containing at least one heteroatom of N, S or O; Q can also be linked to either R1 or R2 to form a 5 to 7 membered alkyl or heteroalkyl ring comprising one or more of O, S or N and R4, R6 and R7 are as defined in the specification. The compounds of formula (I) are useful for treating a disease condition mediated by one or more metalloproteinase enzymes, treating arthritis, atherosclerosis.
|
